title: Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas.
abstract: We report on the safety and feasibility of autologous tumor cell vaccination combined with infusion of granulocyte-macrophage colony-stimulating factor by a programmable pump in the treatment of recurrent malignant gliomas. The programmable pump is a promising tool used to infuse cytokines subcutaneously for vaccination. Our trial enrolled nine patients who had undergone surgery, radiation and had been successfully weaned off steroids. Unfortunately, only five patients completed the protocol and were monitored for side effects, local reactions, delayed-type hypersensitivity (DTH) responses and survival. The treatment was well tolerated. Two patients developed DTH reactions after vaccination and three patients had an unusually long survival without any other treatment. Despite the few patients treated, the results of this trial are encouraging. This study also highlights the specific difficulties encountered in vaccination programs for the treatment of glioma.
authors.affiliation: Département de Neurochirurgie, Centre Hospitalier Universitaire (CHU), 4 rue Larrey, Angers, France. anne.clavreul@univ-angers.fr
authors.forename: Anne
authors.initials: A
authors.lastname: Clavreul
authors.forename: Nicole
authors.initials: N
authors.lastname: Piard
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Tanguy
authors.forename: Eric
authors.initials: E
authors.lastname: Gamelin
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Rousselet
authors.forename: Pierre
authors.initials: P
authors.lastname: Leynia
authors.forename: Philippe
authors.initials: P
authors.lastname: Menei
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000517:prevention & control; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000517:prevention & control; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000295:instrumentation / Q000379:methods; D015918:Infusion Pumps, Implantable; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000517:prevention & control; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
chemical_list: D019496:Cancer Vaccines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor